Qihan Biotech's QT-019B Receives FDA RMAT and BTD
Click to view quick news summary (Spoiler)
Qihan Biotech’s universal allogeneic CAR-T asset, QT-019B, has locked in both RMAT and Breakthrough Therapy designations from the FDA, completing an elite regulatory "triple crown" for Chinese-developed multiplex genome-edited platforms.
Hangzhou Qihan Biotech Co., Ltd. an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced that its internally developed universal dual-target CAR-T therapy, QT-019B, has officially received both Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy Designation (BTD) from the U.S. FDA[cite: 17]. This achievement marks another significant milestone for QT-019B following its receipt of Fast Track Designation (FTD) from the FDA in November 2025[cite: 17].
QT-019B is now among a select group of cell therapy products worldwide to have secured all three of the FDA’s highest-level expedited development and review designations - FTD, RMAT, and BTD[cite: 17]. It is also the first cell therapy product developed in China to earn this FDA “triple crown” of accelerated regulatory designations[cite: 17].
Understanding Regulatory Designations
The Regenerative Medicine Advanced Therapy (RMAT) designation is an FDA expedited program specifically designed for regenerative medicine products, including cell therapies and gene therapies[cite: 17]. The Breakthrough Therapy Designation (BTD) is the FDA’s highest-level expedited development program for therapies intended to treat serious or life-threatening diseases and that may demonstrate substantial improvement over existing treatment options[cite: 17].
Both RMAT and BTD are reserved for therapies that have the potential to provide meaningful improvements over existing treatment options[cite: 17]. The granting of both designations reflects the FDA’s recognition of QT-019B’s promising early clinical profile, supported by encouraging efficacy and safety data[cite: 17]. This dual designation not only reinforces the clinical promise of QT-019B, but also underscores the growing global competitiveness of China’s independently developed universal cell therapy technologies, which are increasingly emerging at the forefront of innovation in the field[cite: 17].
“The achievement of all three of the FDA’s premier expedited development designations for QT-019B underscores both the strength of our scientific platform and the compelling clinical potential of this program,” said Dr. Luhan Yang, Founder and Chief Executive Officer of Qihan Biotech[cite: 17]. “We are committed to working closely with the FDA to accelerate development and bring safe, effective, and accessible universal cell therapies to patients around the world as quickly as possible.”[cite: 17]
About the Off-the-Shelf Allogeneic Asset QT-019B
QT-019B is an off-the-shelf allogeneic CAR-T cell therapy independently developed by Qihan Biotech[cite: 17]. The therapy is derived from healthy donor leukapheresis products and engineered through gene editing to stably express two distinct chimeric antigen receptors (CARs) targeting CD19 and BCMA, allowing simultaneous recognition and elimination of cells expressing either antigen[cite: 17].
To reduce the risk of graft-versus-host disease (GvHD), the T cell receptor (TCR) is knocked out[cite: 17]. Additionally, multiplexable gene editing is employed to induce hypoimmunity, meaning the CAR-T cells are less likely to be recognized and attacked by the patient’s own NK and T cells, thereby reducing immune rejection and cytotoxicity while enhancing persistence[cite: 17].
About Qihan Biotech
Qihan Biotech is a clinical-stage biotechnology company headquartered in Hangzhou, China, founded by Dr. Luhan Yang and Dr. George Church[cite: 17]. The company is advancing off-the-shelf cell therapies through multiplex genome editing, synthetic biology, and scalable GMP manufacturing[cite: 17]. Qihan’s mission is to transform the treatment of severe diseases by integrating multiplex gene editing, hypoimmunity engineering, and targeted in vivo delivery, unlocking universally accessible cell therapies[cite: 17].
